Folic acid supplementation and cancer risk: A meta‐analysis of randomized controlled trials

There are growing data and a continuing controversy over the effect of folic acid supplementation on cancer risk. We conducted a meta‐analysis based on up‐to‐date published relevant randomized trials to further examine this issue. Relative risk (RR) was used to measure the effect of folic acid supplementation on risk of cancer using a random‐effects model. Overall, folic acid supplementation had no significant effect on total cancer incidence (13 trials, n = 49,406, RR = 1.05; 95% CI: 0.99–1.11, p = 0.13), colorectal cancer (seven trials, n = 33,824, 1.01; 0.82–1.23, p = 0.95), other gastrointestinal cancer (two trials, n = 20,228, 1.00; 0.75–1.33, p = 0.99), prostate cancer (five trials, n = 27,065, 1.17; 0.84–1.62, p = 0.35), other genitourinary cancer (two trials, n = 20,228, 0.97; 0.75–1.27, p = 0.84), lung cancer (five trials, n = 31,864, 1.00; 0.84–1.21, p = 0.97), breast cancer (four trials, n = 19,800, 0.82; 0.63–1.07, p = 0.15), hematological malignancy (three trials, n = 25,670, 0.87; 0.64–1.17, p = 0.35) and total cancer mortality (six trials, n = 31,930, 1.02; 0.90–1.15, p = 0.81). However, a significantly reduced risk was observed for melanoma (three trials, n = 19,128, 0.47; 0.23–0.94, p = 0.03). Furthermore, higher total cancer incidence risk was observed among those trials with a higher percent use of lipid‐lowering drugs (>60%, 1.10; 1.00–1.20, p = 0.04), or with lower percent baseline hypertension (≤70%, 1.08; 1.00–1.16, p = 0.057).Consistently, meta‐regression analyses suggested that the similar trend between percent use of lipid‐lowering drugs (p = 0.084) or percent baseline hypertension (p = 0.056) and log‐RR for total cancer incidence associated with folic acid supplementation. Our findings indicate that folic acid supplementation has no significant effect on total cancer incidence, colorectal cancer, prostate cancer, lung cancer, breast cancer or hematological malignancy, but reduces the risk of melanoma.

[1]  Xiping Xu,et al.  Effect of folic acid supplementation on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials. , 2012, Atherosclerosis.

[2]  D. Xavier,et al.  Treatment With B Vitamins and Incidence of Cancer in Patients With Previous Stroke or Transient Ischemic Attack: Results of a Randomized Placebo-Controlled Trial , 2012, Stroke.

[3]  Xiping Xu,et al.  EFFICACY OF FOLIC ACID SUPPLEMENTATION IN STROKE PREVENTION: NEW INSIGHT FROM A META-ANALYSIS , 2012, Heart.

[4]  M. Touvier,et al.  B vitamin and/or ω-3 fatty acid supplementation and cancer: ancillary findings from the supplementation with folate, vitamins B6 and B12, and/or omega-3 fatty acids (SU.FOL.OM3) randomized trial. , 2012, Archives of internal medicine.

[5]  S. Smeland,et al.  Cancer risk with folic acid supplements: a systematic review and meta-analysis , 2012, BMJ Open.

[6]  Xiping Xu,et al.  Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[7]  R. Collins,et al.  Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. , 2010, Archives of internal medicine.

[8]  R. Collins,et al.  Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. , 2010, JAMA.

[9]  J. Heinz,et al.  B Vitamins and the Risk of Total Mortality and Cardiovascular Disease in End-Stage Renal Disease: Results of a Randomized Controlled Trial , 2010, Circulation.

[10]  W. Willett,et al.  A randomized trial on folic acid supplementation and risk of recurrent colorectal adenoma. , 2009, The American journal of clinical nutrition.

[11]  S. Vollset,et al.  Cancer incidence and mortality after treatment with folic acid and vitamin B12. , 2009, JAMA.

[12]  J. Baron,et al.  Folic acid and risk of prostate cancer: results from a randomized clinical trial. , 2009, Journal of the National Cancer Institute.

[13]  R. Detrano,et al.  High-Dose B Vitamin Supplementation and Progression of Subclinical Atherosclerosis: A Randomized Controlled Trial , 2009, Stroke.

[14]  Xiao-Cheng Wu,et al.  Annual Report to the Nation on the Status of Cancer, 1975–2005, Featuring Trends in Lung Cancer, Tobacco Use, and Tobacco Control , 2008, Journal of the National Cancer Institute.

[15]  J. Manson,et al.  Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer risk in women: a randomized trial. , 2008, JAMA.

[16]  S. Vollset,et al.  Angiography : A Randomized Controlled Trial CoronaryWith Homocysteine-Lowering B Vitamins After Mortality and Cardiovascular Events in Patients Treated , 2008 .

[17]  R. Jaszewski,et al.  Folic acid supplementation inhibits recurrence of colorectal adenomas: a randomized chemoprevention trial. , 2008, World journal of gastroenterology.

[18]  P. Guarino,et al.  Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. , 2007, JAMA.

[19]  Elizabeth L. Barry,et al.  Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. , 2007, JAMA.

[20]  Xiping Xu,et al.  Efficacy of folic acid supplementation in stroke prevention: a meta-analysis , 2007, The Lancet.

[21]  Per Magne Ueland,et al.  Homocysteine lowering and cardiovascular events after acute myocardial infarction. , 2006, The New England journal of medicine.

[22]  G. Davey Smith,et al.  Taking folate in pregnancy and risk of maternal breast cancer , 2005, BMJ : British Medical Journal.

[23]  E. Rimm,et al.  Folate Intake and the Risk of Incident Hypertension Among US Women , 2006 .

[24]  L. Chambless,et al.  Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. , 2004, JAMA.

[25]  S. Thompson,et al.  How should meta‐regression analyses be undertaken and interpreted? , 2002, Statistics in medicine.

[26]  D. Cook,et al.  Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? , 1998, The Lancet.

[27]  G. Paspatis,et al.  Folate supplementation and adenomatous colonic polyps , 1994, Diseases of the colon and rectum.

[28]  A. Czeizel,et al.  Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. , 1992, The New England journal of medicine.

[29]  R. Koppensteiner,et al.  High-dose atorvastatin treatment in patients with peripheral arterial disease: effects on platelet aggregation, blood rheology and plasma homocysteine. , 2011, Clinical hemorheology and microcirculation.

[30]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[31]  R. Collins,et al.  Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) , 2009 .

[32]  K. Muir,et al.  Aspirin and folic acid for the prevention of recurrent colorectal adenomas. , 2008, Gastroenterology.

[33]  M. Righetti.  Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients , 2007, Clinical chemistry and laboratory medicine.

[34]  A. A. Liakishev.  [Homocysteine lowering with folic acid and B vitamins in vascular disease]. , 2006, Kardiologiia.

[35]  J. Mason,et al.  The effect of folic acid on the development of stomach and other gastrointestinal cancers. , 2003, Chinese medical journal.